Trials / Completed
CompletedNCT01303380
Canakinumab in Patients With Active Hyper-IgD Syndrome
An Open-label, Multicenter, Efficacy and Safety Pilot Study of 6-month Canakinumab Treatment With up to 6-month Follow-up in Patients With Active Hyper-IgD Syndrome (HIDS)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 24 Months
- Healthy volunteers
- Not accepted
Summary
This pilot study is designed to evaluate the efficacy, the safety, and the pharmacokinetics (PK) / pharmacodynamics (PD) of canakinumab treatment in patients with HIDS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Canakinumab |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2011-02-24
- Last updated
- 2015-11-05
- Results posted
- 2015-08-19
Locations
3 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT01303380. Inclusion in this directory is not an endorsement.